Angiotensin receptor blockers and the cardiovascular continuum: What future is indicated by recent successes?

European Heart Journal, Supplement

Volumn 5, Issue C, 2003, Pages

  Weber, M A ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Cardiovascular protection; Diabetes; Heart failure; Myocardial infarction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN; NATEGLINIDE; VALSARTAN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT;

EID: 0037377034     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(03)90042-3     Document Type: Conference Paper

References (19)

1. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
2. Viberti G, Wheeldon NM, for the MARVAL study investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure independent effect. Circulation 2002;106:672-8.
3. Parving H-H, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
4. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345: 861-9.
5. Dahlöf B, Devereux R, Kjeldsen S et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
6. Cohn JN, Tognoni G, the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
7. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121:1244-63.
8. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
9. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355: 1582-7.
10. Dickstein K, Kjekshus J, the OPTIMAAL Steering Committee for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
11. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998;7: 176-83.
12. Pfeffer MA, McMurray J, Leizorovicz A et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-50.
13. Haffner S, Holman R, Califf R et al. Targeting post-prandial hyperglycemia to prevent type 2 diabetes: Rationale and design of the NAVIGATOR trial. Presented at the 38th Annual Meeting of the European Association for the Study of Diabetes. Budapest, Hungary; 3 September 2002.
14. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
15. Bart BA, Ertl G, Held P et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 1999;20:1182-90.
16. Swedberg K, for the CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429-35.
17. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
18. Maggioni A, Anand I, Gottlieb S et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving ACE-inhibitors. J Am Coll Cardiol 2002;40:1414-21.
19. Hansson L, Lithell H. The study on cognition and prognosis in elderly hypertensives (SCOPE). Data presented at the 19th Scientific Meeting of the International Society of Hypertension and the 12th European Meeting on Hypertension - European Society of Hypertension. Prague, Czech Republic; 23-27 June 2002.